ALZHEIMER’S DISEASE

At the Hermanos Ameijeiras Surgical Clinical Hospital in Havana, consultations began this Wednesday to classify patients with Alzheimer's disease for their subsequent inclusion in the Phase III clinical trial with the neuroprotective drug NeuralCIM (NeuroEPO).»

NeuroEPO, Cuba's neuroprotective drug to counteract mild and moderate Alzheimer's disease, concluded phase II/III studies and a stage IV of progressive introduction of the product is being prepared, a scientific authority noted on Monday.»

The Center for State Control of Medicines, Equipment and Medical Devices (CECMED) approved a conditional sanitary registration of Neuro-Epo, a drug from the Molecular Engineering Center with neuroprotective properties for the treatment of mild and moderate Alzheimer's disease.»